Proportion of malaria provinces with diagnosis, cases receiving treatment. direct observed Procurement of 160,000 LLINs. treatment in tier 1 increases to 95% by 2015. 110,000 LLINs distributed to populations in endemic areas in tier 1 and 2. 200 private practitioners/drug sellers trained annually on new guidelines and drug resistance. Objective 6: Limit the availability of oral artemisinin-based monotheraphy, substandard and counterfeit antimalarial medicine while improving quality of ACTs Reduced availability Surveys in the containment areas Unlikely to achieve within the Only approximately 15% of the 2014 Risk: of oral showing fall in availability of oral project timeframe. Workplan completed. High regional political monotherapy artemisinin-based monotherapy. Developed a 3-year action plan Only one out of four milestones in commitment of the (oAMT) in the Meeting report showing available through a Stakeholder meeting on 2014 achieved and two are ongoing. regional authorities containment areas. data shared on drug quality. Pharmaceutical Systems not obtained and lack Need to address availability of quality Data available on Strengthening participated by of funding to improve Company survey showing anti-malaria drugs through drug quality of medicines regulatory authorities, broader reduced number of companies improvements to the broader artemisinin-based pharmaceutical law enforcement, pharmaceutical producing oral pharmaceutical system which is combination therapy NMCPs and key partners. system. beyond a 3-year emergency project (ACT) shared Number of countries in GMS Supported Cambodia, China, Lao Low enforcement of annually. started enforcing the ban on oral Three-year plan not fully funded. PDR, and Vietnam to develop oAMTs bans of each artesunate monotherapies. Reduced number of country strategies on how to country. Need to look at an alternative so the companies producing eliminate oAMTs. Details for objective is maintained, for example,
Proportion of malaria cases receiving direct observed treatment in tier 1 increases to 95% by 2015. 110,000 LLINs distributed to populations in endemic areas in tier 1 and 2. 200 private practitioners/drug sellers trained annually on new guidelines and drug resistance. provinces with diagnosis, treatment. Procurement of 160,000 LLINs. Objective 6: Limit the availability of oral artemisinin-based monotheraphy, substandard and counterfeit antimalarial medicine while improving quality of ACTs Reduced availability of oral monotherapy (oAMT) in the containment areas. Data available on drug quality of artemisinin-based combination therapy (ACT) shared annually. Reduced number of companies producing Surveys in the containment areas showing fall in availability of oral artemisinin-based monotherapy. Meeting report showing available data shared on drug quality. Company survey showing reduced number of companies producing oral Number of countries in GMS started enforcing the ban on oral artesunate monotherapies. Unlikely to achieve within the project timeframe. Developed a 3-year action plan through a Stakeholder meeting on Pharmaceutical Systems Strengthening participated by medicines regulatory authorities, pharmaceutical law enforcement, NMCPs and key partners. Supported Cambodia, China, Lao PDR, and Vietnam to develop country strategies on how to eliminate oAMTs. Details for Only approximately 15% of the 2014 Workplan completed. Only one out of four milestones in 2014 achieved and two are ongoing. Need to address availability of quality anti-malaria drugs through improvements to the broader pharmaceutical system which is beyond a 3-year emergency project Three-year plan not fully funded. Need to look at an alternative so the objective is maintained, for example, Risk: High regional political commitment of the regional authorities not obtained and lack of funding to improve broader pharmaceutical system. Low enforcement of oAMTs bans of each country.
coordination-of-the-emergency-response-to-artemisinin-resistance-independent-mid-term-review.docx